Compare YSS & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSS | LGND |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | United States | United States |
| Employees | 710 | 68 |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 3.7B |
| IPO Year | N/A | N/A |
| Metric | YSS | LGND |
|---|---|---|
| Price | $17.06 | $300.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $36.56 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 1.1M | 354.1K |
| Earning Date | 03-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $48.43 | $1.25 |
| Revenue Next Year | $52.83 | $19.41 |
| P/E Ratio | ★ N/A | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.93 | $131.67 |
| 52 Week High | $44.54 | $326.63 |
| Indicator | YSS | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 31.61 | 54.03 |
| Support Level | N/A | $290.20 |
| Resistance Level | $35.56 | $326.63 |
| Average True Range (ATR) | 1.74 | 10.96 |
| MACD | -0.13 | -3.74 |
| Stochastic Oscillator | 1.91 | 24.94 |
York Space Systems Inc is a U.S.-based space and defense company that provides mission-related solutions for national security, government, and commercial customers. The company develops its own hardware and software, offering capabilities intended to support customer requirements across various elements of the space mission lifecycle. It offers mission solutions across several complementary product categories: Components, Subsystems, Spacecraft Platforms, Ground Operation, Global Downlink, and Software-Enabled Services. The company derives the majority of revenue from long-term firm-fixed-price (FFP) production contracts for the design of small satellites, launch services, and ground services with both U.S. federal government-controlled agencies and domestic commercial customers.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.